latanoprost / Generic mfg. - LARVOL DELTA

Effect of Latanoprost and Timolol-Dorzolamide Therapy on Aqueous Humor Cytokine Concentrations in Patients with Pseudoexfoliative Glaucoma. (PubMed, Medicina (Kaunas)) - "These findings support the presence of low-grade inflammation in patients with PEXG that does not differ according to the therapy administered. Corneal endothelial alterations are disease-related rather than treatment-induced."

Journal • Observational data • Cataract • Glaucoma • Oncology • Ophthalmology • CXCL8 • IL10 • IL1B • IL6 • TNFA

Effect of Prostaglandin Analogues on Hyaluronan Production of Orbital Fibroblasts. (PubMed, Biomedicines) - "Cultures were performed with or without platelet-derived growth factor BB (PDGF-BB) stimulation, and treated for 72 h with 40 µM prostaglandin F2α (PGF2α), latanoprost, bimatoprost or tafluprost. These in vitro findings suggest that PGAs modulate HA turnover in orbital fibroblasts through reduced HA synthesis and potentially enhanced degradation. While these observations are confined to cultured cells, they offer a hypothesis for potential clinical relevance in TED, which requires further in vivo validation."

Journal • Ophthalmology • Thyroid Eye Disease • CEMIP • HAS 3 • HAS1 • HAS2 • HYAL1

Concomitant limaprost use and intraocular pressure response to latanoprost in normal-tension glaucoma: A retrospective cohort study. (PubMed, Medicine (Baltimore)) - "In a secondary exploratory subgroup of 63 patients who subsequently received add-on dorzolamide/timolol, 35 were in the limaprost group and 28 were controls; no statistically significant between-group difference in IOP reduction was detected. Concomitant limaprost use was associated with a modestly smaller observed IOP reduction after latanoprost treatment in patients with NTG. Because of the retrospective design and the modest magnitude of the association, prospective studies are needed to determine whether a clinically meaningful pharmacologic interaction exists."

Journal • Retrospective data • Cardiovascular • Diabetes • Glaucoma • Hypertension • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Ocular Surface Symptoms, Objective Redness, and Intraocular Pressure After a Switch from Fixed Dorzolamide/Timolol to Netarsudil in Latanoprost-Treated Glaucoma and Ocular Hypertension: A Prospective Real-World Cohort Study. (PubMed, Medicina (Kaunas)) - " The switch was associated with modest OSDI improvement and maintained short-term IOP control despite increased objective redness. Patient preference appeared to reflect factors beyond redness alone."

Journal • Observational data • Real-world evidence • Cardiovascular • Glaucoma • Ophthalmology

From a Fish Protein to a Novel Glaucoma Therapeutic: Stanniocalcin-1 for Intraocular Pressure Reduction. (PubMed, Adv Ophthalmol Optom) - No abstract available

Journal • Glaucoma • Ophthalmology • STC • STC1

Ocular microdialysis in preclinical pharmacokinetic studies: Principles, challenges, and practical insights. (PubMed, J Pharm Sci) - "To contextualize these considerations, a case study investigating the ocular PK of the prostaglandin analog prodrug latanoprost is presented. Experimental results highlight the impact of temporal lag and recovery calibration on ocular PK interpretation and demonstrate that microdialysis-derived exposure profiles can closely recapitulate human ocular PK under comparable conditions. Finally, best-practice recommendations are proposed to help guide experimental design, recovery estimation, data interpretation, and translational relevance of future ocular microdialysis studies."

Journal • PK/PD data • Preclinical • Review • Ophthalmology

Prediction of Ocular Toxicity of Prostaglandin F2α Analogs Based on Local Computational Models: Superiority over Global Models and Experimental Validation. (PubMed, Molecules) - "Virtual molecular docking was employed to explore the mechanism, and all analogs docked favorably into the quinone-binding channel of mitochondrial complex I and the catalytic cleft of SIRT3. These results show how a localized modeling approach is better able to capture structure-toxicity correlations among chemically similar compounds and highlight the critical need for rigorous impurity management in latanoprost products, particularly regarding 15(S)-latanoprost."

Head-to-Head • Journal • Glaucoma • Ophthalmology • SIRT3

Prostaglandin Analogues Attenuate Hyaluronan Accumulation in Orbital Fibroblast Cultures (ETA 2026) - "Cells were cultured in the presence or absence of PGAs: latanoprost, tafluprost or bimatoprost, or prostaglandin F2 (PF2), with or without PDGF-BB (10 ng/ml) stimulation of HA synthesis. PGAs modulate HA levels in orbital fibroblasts not only by suppressing synthesis but also by promoting degradation. This dual action may offer therapeutic benefits in TED, where the progression of the disease is driven by pathological HA accumulation."

Glaucoma • Ophthalmology • Thyroid Eye Disease • CEMIP • HAS 3 • HAS1 • HAS2 • HYAL1

Latanoprost Acid-Brimonidine, a New Amide Prodrug for Glaucoma Management Based on the Concept of Sustained Release. (PubMed, Molecules) - "In the presence of esterase (0.4 U/mL), the hydrolysis times of LP and LBJ were 4 h and 28 days, respectively. The prolonged hydrolysis time results in sustained APIs release, which is beneficial for the development of a sustained drug release system."

Journal • Glaucoma • Ophthalmology

Exploratory Analysis of Glaucoma-Associated SNPs in a Colombian Cohort Highlights Potential Involvement of Oxidative, Vascular, and Neurodegenerative Pathways. (PubMed, Genes (Basel)) - "This exploratory analysis identifies known glaucoma-associated variants, rare candidate variants, and pharmacogenomic markers in Colombian patients with POAG. The findings support a multifactorial biological framework involving interconnected oxidative, structural, vascular, neurodegenerative, and inflammatory pathways. The FMNL2 and C3 variants represent candidates for further investigation, while the identified pharmacogenomic variants highlight the potential relevance of genomic profiling for personalized glaucoma management. Larger ancestry-informed case-control studies are required to validate these observations and determine their clinical significance."

Journal • CNS Disorders • Glaucoma • Inflammation • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • CYP1B1 • NOS3 • PTGS1 • SOD2

Intraocular pressure reduction attenuates form-deprivation myopia by modulating scleral extracellular matrix remodeling via the TGF-β1/Smad signaling pathway. (PubMed, Exp Eye Res) - "Intraocular pressure reduction achieved separately via two mechanistically distinct pharmacological approaches mitigates FDM by preserving scleral integrity through modulation of ECM remodeling, an effect mediated via activation of the TGF-β1/Smad signaling pathway."

Journal • Ophthalmology • MMP2 • SMAD3 • TGFB1 • TIMP2

Daily Topical Latanoprost Free Acid Exacerbates Retinal Ganglion Cell Degeneration in the DBA/2J Mouse Model of Pigment Dispersion Glaucoma. (PubMed, Prostaglandins Other Lipid Mediat) - "DZ lowered IOP without notable retinal side effects. In contrast, LFA reduced IOP but was associated with enhanced RGC neurodegeneration and increased neuroinflammation. Further studies are needed to determine whether LFA-mediated changes are specific to the DBA/2J mouse or if other models with underlying pro-inflammatory microenvironments may be susceptible to RGC loss with prostaglandin analog therapy."

Journal • Preclinical • Review • Cardiovascular • CNS Disorders • Glaucoma • Inflammation • Ophthalmology • GFAP • RBPMS

Can pilocarpine effectively and safely manage glaucoma in the modern era? A systematic review and meta-analysis. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Subgroup analyses suggested larger pooled effects in placebo/no-treatment comparisons, ocular hypertension, primary open-angle glaucoma, and monotherapy studies; however, comparisons with beta-blockers and prostaglandin analogs require cautious interpretation because several large individual trials favored timolol or latanoprost for daily clinical use, tolerability, or dosing convenience. Pilocarpine lowers IOP effectively, but its modern role is limited by frequent dosing, miosis, blurred vision, accommodative symptoms, brow ache, and higher discontinuation. In current glaucoma care, prostaglandin analogs and selective laser trabeculoplasty are generally more consistent with first-line open-angle glaucoma management, whereas pilocarpine is better positioned for selected clinical scenarios, including angle-closure mechanisms, post-laser pressure-spike prophylaxis, selected postoperative angle-surgery settings, intolerance or nonresponse to other drug classes, and..."

Journal • Retrospective data • Review • Cardiovascular • Glaucoma • Ophthalmology • Pain

Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata (clinicaltrials.gov) - P=N/A | N=80 | Completed | Sponsor: Tanta University

New trial • Alopecia • Dermatology • Immunology

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Biomarker • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Black Elderberry Exposure in Apparent Idiopathic Mild Acute Pancreatitis: A Case Report. (PubMed, Cureus) - "Medication reconciliation revealed daily use of black elderberry extract along with chronic losartan, atenolol, niacin, aspirin, and latanoprost. Because occult biliary disease and medication co-exposure could not be definitively excluded, causality was conservatively classified as possible black elderberry-associated acute pancreatitis. This case reviews the importance of explicit supplement reconciliation in apparent idiopathic acute pancreatitis and the need for endoscopic ultrasound or magnetic resonance cholangiopancreatography after recovery in older adults when initial evaluation is unrevealing."

Journal • Cardiovascular • Dyslipidemia • Hepatology • Hypertension • Pain • Pancreatitis

Firecrest: Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P2/3 | N=64 | Completed | Sponsor: Qlaris Bio, Inc. | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Punctal and Intracanalicular Drug Delivery Systems for Ophthalmic Use: A Narrative Review of Technologies, Clinical Outcomes, and Critical Quality Attributes. (PubMed, Pharmaceutics) - "DEXTENZA® (dexamethasone) is FDA-approved for postoperative inflammation, whereas pivotal trials of travoprost (OTX-TP) and latanoprost systems (L-PPDS, EXP-LP) did not demonstrate superiority over placebo or eye drops. We propose the following candidate CQAs: retention (>80% over 4 weeks), swelling degree (30-60%), controlled burst release (<40% within 24 h), and mechanical compatibility. The proposed QTPP matrices for punctal, intracanalicular, and in situ systems may guide the development of ophthalmic drug delivery platforms."

Clinical data • Journal • Review • Inflammation • Ocular Inflammation • Ophthalmology

Glaucoma prevalence and prescribing trends in New Zealand: A 10-year study. (PubMed, Asia Pac J Ophthalmol (Phila)) - "This nationwide study provides the most comprehensive analysis to date of glaucoma medication dispensing in Aotearoa New Zealand, capturing real-world treatment patterns across a ten-year period. It offers critical insight into the treated prevalence and incidence of pharmacologically treated glaucoma and ocular hypertension at a population level. Latanoprost has clearly emerged as the dominant first-line therapy, consistent with international clinical guidelines, followed by Timolol. However, the findings also expose significant inequities: Māori-the Indigenous people of New Zealand-and Pasifika populations remain markedly under-represented among those receiving glaucoma treatment, even after adjusting for age. Further research is needed to understand the underlying reasons for these disparities and to ensure equitable access to glaucoma care for all New Zealanders."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Changes in Corneal Epithelial Barrier Function and Zonula Occludens-1 Distribution with Concomitant Use of Silver Nitrate and Latanoprost in Rabbits. (PubMed, J Ocul Pharmacol Ther) - "A high concentration of AgNO3 with LP exacerbated corneal epithelial barrier impairment, which highlights the importance of preservative concentration control in ophthalmic formulations."

Journal • Preclinical • Ophthalmology • TJP1

Optic Nerve Head Strain in Non-glaucoma Subjects (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Johns Hopkins University | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of prostaglandin F2α receptor activation. (PubMed, Pharmacol Rep) - P=N/A | "In this pilot proof-of-concept trial, topical latanoprost acid showed a coherent clinical-trichoscopic bioactivity signal, supported by FP receptor-linked signaling in HHDPCs. These findings require confirmation in larger randomized pharmacokinetic/pharmacodynamic-integrated trials designed to optimize dose, confirm efficacy, and further characterize long-term safety."

Clinical • Journal • Alopecia • Immunology • FUS

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P2 | N=75 | Active, not recruiting | Sponsor: PolyActiva Pty Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Glaucoma • Ophthalmology

Firecrest: Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P2/3 | N=60 | Active, not recruiting | Sponsor: Qlaris Bio, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Glaucoma • Ophthalmology

Efficacy and Safety of Microneedling Combined With Mesotherapy for Androgenic Alopecia: A Retrospective Study Comparing Four Treatment Protocols. (PubMed, Health Sci Rep) - "All groups received microneedling therapy combined with different mesotherapy formulations: Group I (n = 16) received 2 mL hyaluronic acid (HA); Group II (n = 20) received 1.5 mL HA plus 0.5 mL finasteride; Group III (n = 15) received 1.5 mL HA plus 0.5 mL latanoprost; and Group IV (n = 12) received 1 mL HA plus 0.5 mL finasteride and 0.5 mL latanoprost. All treatment protocols were well-tolerated with minimal adverse effects. The findings of the current study support the use of combination mesotherapy protocols for enhanced therapeutic outcomes in AGA management."

Journal • Retrospective data • Alopecia • Immunology